{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:53:44Z","timestamp":1790664824750,"version":"4.1.0"},"reference-count":36,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015406","name":"Tianjin Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["20YFZCSY00800"],"award-info":[{"award-number":["20YFZCSY00800"]}],"id":[{"id":"10.13039\/501100015406","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800105"],"award-info":[{"award-number":["81800105"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970180"],"award-info":[{"award-number":["81970180"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are usually associated with poor outcomes, especially in high\u2010risk AML\/MDS. Allogeneic hematopoietic stem cell transplantation (allo\u2010HSCT) is the only curative option for patients suffering from high\u2010risk AML\/MDS. However, many patients relapse after allo\u2010HSCT. Novel therapy to prevent relapse is urgently needed. Both the BCL\u20102 inhibitor venetoclax (VEN) and the hypomethylating agent decitabine (DEC) possess significant antitumor activity effects against AML\/MDS. Administration of DEC has been shown to ameliorate graft\u2010versus\u2010host disease (GVHD) and boost the graft\u2010versus\u2010leukemia (GVL) effect post\u2010transplantation. We therefore conducted a prospective study (ChiCTR1900025374) to examine the tolerability and efficacy of a maintenance therapy of low\u2010dose decitabine (LDEC) plus VEN to prevent relapse after allo\u2010HSCT for high\u2010risk AML\/MDS patients. Twenty patients with high\u2010risk AML (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a017) or high\u2010risk MDS (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a03) post\u2010transplantation were recruited. Approximately day 100 post\u2010transplantation, all patients received LDEC (15\u00a0mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    for 3\u00a0d) followed by VEN (200\u00a0mg) on d 1\u201021. The cycle interval was 2 mo, and there was 10 cycles. The primary end points of this study were rates of overall survival (OS) and event\u2010free survival (EFS). The secondary endpoints included adverse events (AEs), cumulative incidence of relapse (CIR), nonrelapse mortality (NRM), incidences of acute GVHD (aGVHD) and chronic GVHD (cGVHD), and incidences of viral infection after allo\u2010HSCT. Survival outcomes were assessed using Kaplan\u2010Meier analysis. The median follow\u2010up was 598 (149\u20101072) d. Two patients relapsed, 1 died, and 1 is still alive after the second transplant. The 2\u2010y OS and EFS rates were 85.2% and 84.7%, respectively. The median 2\u2010y EFS time was 525 (149\u20101072) d, and 17 patients still had EFS and were alive at the time of this writing. The most common AEs were neutropenia, anemia, thrombocytopenia, neutropenic fever, and fatigue. Grade 2 or 3 AEs were observed in 35% (7\/20) and 20% (4\/20) of the patients, respectively. No grade &gt;3 AEs were observed. aGVHD (any grade) and cGVHD (limited or extensive) occurred in 55% and 20% of patients, respectively. We conclude that LDEC\u00a0+\u00a0VEN can be administered safely after allo\u2010HSCT with no evidence of an increased incidence of GVHD, and this combination decreases the relapse rate in high\u2010risk AML\/MDS patients. This novel maintenance therapy may be a promising way to prevent relapse in high\u2010risk AML\/MDS patients.\n                  <\/jats:p>","DOI":"10.1111\/cas.15048","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T14:52:45Z","timestamp":1624978365000},"page":"3636-3644","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Low\u2010dose decitabine plus venetoclax is safe and effective as post\u2010transplant maintenance therapy for high\u2010risk acute myeloid leukemia and myelodysplastic syndrome"],"prefix":"10.1111","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0088-7775","authenticated-orcid":false,"given":"Yunxiong","family":"Wei","sequence":"first","affiliation":[{"name":"The First Central Clinical College of Tianjin Medical University Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Xiong","sequence":"additional","affiliation":[{"name":"The First Central Clinical College of Tianjin Medical University Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"The First Central Clinical College of Tianjin Medical University Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Hematology Tianjin First Central Hospital Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"He","sequence":"additional","affiliation":[{"name":"Department of Hematology Tianjin First Central Hospital Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Jin","sequence":"additional","affiliation":[{"name":"Nankai University School of Medicine Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[{"name":"Nankai University School of Medicine Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Lyu","sequence":"additional","affiliation":[{"name":"Department of Hematology Tianjin First Central Hospital Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Hematology Tianjin First Central Hospital Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongtong","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiology First Central Clinical College Tianjin Medical University Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5995-7558","authenticated-orcid":false,"given":"Mingfeng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology Tianjin First Central Hospital Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"National Cancer Institute Surveillance Epidemiology and End Results Program.Cancer stat facts: acute myeloid leukemia (AML) [Internet].https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.htmlCited June 1 2020."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21699"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30158-9"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2012.150"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1695053"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12720"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-375840"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001482"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1775214"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0347-6"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25352"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16682"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21792"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.9178"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-257253"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-210393"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-014-0059-3"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.05.026"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0472-9"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.326"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25500"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30680"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0774"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-138832"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0612-8"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2015.03.005"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.02.010"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25929"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12336"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0759"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0233-1"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.01.013"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0677-z"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12629"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12877"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.15048","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cas.15048","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.15048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T20:52:47Z","timestamp":1692564767000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.15048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1111\/cas.15048"],"URL":"https:\/\/doi.org\/10.1111\/cas.15048","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,21]]},"assertion":[{"value":"2021-03-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}